Clinical trial · Observational
Circulating Biomarkers to Identify Thyroid Cancer
Using Circulating Biomarkers to Identify Thyroid Cancer From the Patients With Thyroid Nodules
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to identify the potential circulating biomarkers of protein, mRNAs, and long non-coding RNAs (lncRNAs) to differentiate the papillary thyroid cancers from benign thyroid tumors. Methods: The study population of 100 patients was classified into identification (10 patients with papillary thyroid cancers and 10 patients with benign thyroid tumors) and validation groups (45 patients with papillary thyroid cancers and 35 patients with benign thyroid tumors). The Sengenics Immunome Protein Array combined data mining approach using the Open Targets Platform was used to identify the putative protein biomarkers, and their expression validated using the enzyme-linked immunosorbent assay. Next-generation sequencing by Illumina HiSeq was used for the detection of dysregulated mRNAs and lncRNAs. The website Timer v2.0 helped identify the putative mRNA biomarkers, which were significantly over-expressed in papillary thyroid cancers than in adjacent normal thyroid tissue. The mRNA and lncRNAs biomarker expression was validated by a real-time polymerase chain reaction.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Thyroid Tumor | Benign Thyroid Gland Neoplasm | ALIAS | 0.90 |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
| Thyroid Cancer, Papillary | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Identification group | Other | — | UNRESOLVED |
| Validation group | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Thyroid cancers
- description
- Enrolled study population have papillary thyroid cancers and benign thyroid tumors
- interventionNames
- Other: Identification group
- Other: Validation group
Primary outcomes (1)
- measure
- Stage of thyroid cancers
- timeFrame
- 1 months after surgery
- description
- The final diagnosis of malignant or benign lesions was based on the pathological reports.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with thyroid nodules who received total or subtotal thyroidectomy * Patients aged 20 years and above Exclusion Criteria: * Patients with any other type of cancer, immunocompromised disease, or autoimmune disease.
References
Publications (0)
Data not yet available